| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5750497 | NOVO NORDISK INC | Acylated insulin |
Jun, 2019
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
| US9486588 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US6899699 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8672898 | NOVO NORDISK INC | Automatic injection device with reset feature |
Jan, 2022
(2 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(19 days from now) | |
| US8684969 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Oct, 2025
(1 year, 5 months from now) | |
| US9861757 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10357616 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US10376652 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9616180 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9108002 | NOVO NORDISK INC | Automatic injection device with a top release mechanism |
Jan, 2026
(1 year, 8 months from now) | |
| US9775953 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| US10220155 | NOVO NORDISK INC | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(2 years from now) | |
| US8920383 | NOVO NORDISK INC | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(2 years from now) | |
| USRE46363 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US7686786 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Aug, 2026
(2 years from now) | |
| US9687611 | NOVO NORDISK INC | Injection device with torsion spring and rotatable display |
Feb, 2027
(2 years from now) | |
| US9457154 | NOVO NORDISK INC | Injection device with an end of dose feedback mechanism |
Sep, 2027
(3 years from now) | |
| US9132239 | NOVO NORDISK INC | Dial-down mechanism for wind-up pen |
Feb, 2032
(7 years from now) | |
Levemir Flextouch is owned by Novo Nordisk Inc.
Levemir Flextouch contains Insulin Detemir Recombinant.
Levemir Flextouch has a total of 21 drug patents out of which 6 drug patents have expired.
Expired drug patents of Levemir Flextouch are:
- US5866538
- US9486588
- US6899699
- US8672898
- US8579869
- US5750497
Levemir Flextouch was authorised for market use on 31 October, 2013.
Levemir Flextouch is available in injectable;subcutaneous dosage forms.
Levemir Flextouch can be used as levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
The generics of Levemir Flextouch are possible to be released after 01 February, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXTOUCH family patents
